ALG-093453

ALG-093453 is an **oral, liver-targeted small-molecule programmed death-ligand 1 inhibitor** being developed by **Aligos Therapeutics** as an immunomodulatory therapy for **chronic hepatitis B**. The compound was rationally designed to achieve **liver specificity** and improved tolerability while maintaining potency comparable to approved checkpoint-directed antibody therapies. Preclinical data described for ALG-093453 indicate that it can **block the PD-L1 immune checkpoint pathway and activate HBV-specific T-cell cultures**, supporting its use as a liver-directed immunotherapy intended to restore antiviral immune responses in chronic HBV infection.